- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02377752
A Study of Olaratumab in Japanese Participants With Advanced Cancer
A Phase 1 Study of Olaratumab in Japanese Patients With Advanced Soft Tissue Sarcoma or Advanced Solid Tumors
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Chuo-Ku, Japon, 104-0045
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
Koto-ku, Japon, 135-8550
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
Nagoya, Japon, 466-8560
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
Suita-shi, Japon, 565-0871
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Part A: Have histological or cytological evidence of a diagnosis of advanced or metastatic solid tumor, especially STS, which is not amenable to treatment with surgery or radiotherapy. Part B: Have histological or cytological evidence of a diagnosis of solid tumor that is advanced or metastatic.
- Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
- Have given written informed consent prior to any study-specific procedures.
- Have adequate organ and coagulation function
- Have an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of less than or equal to 1.
- Have discontinued previous treatments for cancer and recovered from the acute effects of therapy.
- (Part A only) Have a prestudy echocardiogram with an actual left ventricular ejection fraction greater than or equal to 50%, within 21 days prior to first dose of study medication.
- All participants agree to use a reliable method of birth control and to not donate sperm during the study and for at least 3 months following last dose of study drug.
Female participants:
- must either be women not of child-bearing potential due to surgical sterilization confirmed by medical history, or menopause or
- women of child-bearing potential who test negative for pregnancy within 7 days before the first dose of study drug based on serum or urine pregnancy test and agree not to breast feed during the study and for 3 months following the last dose of the study drug(s)
- Have an estimated life expectancy of more than or equal to 3 months in the judgment of the investigator.
Exclusion Criteria:
- Have received treatment within 21 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device for non-cancer indications or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- (Part A only) Have received prior treatment with doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
- (Part A only) Have received prior radiation therapy to the mediastinal/pericardial area.
- Have symptomatic central nervous system malignancy or metastasis. Participants with treated central nervous system (CNS) metastases are eligible for this study if they are not currently receiving corticosteroids and/or anticonvulsants, and their disease is asymptomatic and radiographically stable for at least 60 days.
- Have an elective or a planned major surgery to be performed during the course of the study.
- Have an uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure greater than class II of the New York Heart Association guideline, severe myocardial insufficiency, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Have unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months prior to study entry.
- Have a known allergy to any of the treatment components.
- Have a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of olaratumab.
- Have a known active fungal, bacterial, and/or known viral infection
- Have a corrected QT interval of greater than 470 milliseconds (msec) on screening electrocardiogram (ECG)
- Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Part A cohort 1: Olaratumab+Doxorubicin
15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met . |
Administré IV
Autres noms:
Administré IV
|
Expérimental: Part A cohort 2: Olaratumab+Doxorubicin
15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles.
Participants may continue to receive treatment until discontinuation criteria are met.
|
Administré IV
Autres noms:
Administré IV
|
Expérimental: Part A cohort 3 Olaratumab + Doxorubicin
20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles.
Participants may continue to receive treatment until discontinuation criteria are met.
|
Administré IV
Autres noms:
Administré IV
|
Expérimental: Part B: Olaratumab
15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle.
Participants may continue to receive treatment until discontinuation criteria are met.
|
Administré IV
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Part A: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Délai: Baseline to Study completion (Up To 3.5 Years)
|
Clinically significant events were defined as serious adverse events (SAE).
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
|
Baseline to Study completion (Up To 3.5 Years)
|
Part A: Number of Participants With Dose Limiting Toxicities (DLTs)
Délai: Cycle 1 (21 Days)
|
DLT is defined as adverse event (AE) during Cycle 1 (Days 1 through 21) that was possibly related to the study drug and toxicities considered by the investigator as dose limiting.
A summary of other nonserious AEs, and all serious adverse events (SAE's), regardless of causality, is located in the Reported Adverse Events section.
|
Cycle 1 (21 Days)
|
Part B: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Olaratumab
Délai: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Maximum observed serum concentration (Cmax) of olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Part B: Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of Olaratumab
Délai: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
AUC(0-t) hours (h), area under the serum concentration versus time curve from time zero to t hours at AUC(0-168h) for Cycle 1 Day 1 and Cycle 3 Day 1, AUC(0-336h) for Cycle 1 Day 8 and Cycle 3 Day 8 of Olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Part A: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Olaratumab
Délai: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Maximum observed serum concentration (Cmax) of olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Part A: Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of Olaratumab
Délai: Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
AUC(0-t) hours (h), area under the serum concentration versus time curve from time zero to t hours at AUC(0-168h) for Cycle 1 Day 1 and Cycle 3 Day 1, AUC(0-336h) for Cycle 1 Day 8 and Cycle 3 Day 8 of Olaratumab is reported.
|
Cycle (C) 1 Day (D) 1 and C3 D1: Pre-infusion, Immediately postinfusion and 1.5, 24, 48, 72 and 168 hours (h) postinfusion; C1 D8 and C3 D8: Pre- infusion, Immediately postinfusion and 1, 48, 72, 168 and 336 h postinfusion
|
Part A: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Doxorubicin
Délai: Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 3 Day 1, Cycle 3 Day 2 and Cycle 3 Day 3: Immediately postinfusion
|
Maximum observed plasma concentration (Cmax) of doxorubicin is reported.
|
Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 3 Day 1, Cycle 3 Day 2 and Cycle 3 Day 3: Immediately postinfusion
|
Part A: Pharmacokinetics: Maximum Observed Concentration (Cmax) of Doxorubicin
Délai: Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Maximum observed plasma concentration (Cmax) of doxorubicin is reported.
|
Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Part A: Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of Doxorubicin
Délai: Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Area under the concentration verses time curve from zero to infinity (AUC[0-∞]) of doxorubicin is reported.
|
Cycle 1 Day 1 and Cycle 3 Day 1: Immediately postinfusion, 0.5, 1, 2, 4, 8, 24, 48, and 72 h postinfusion
|
Change From Baseline in Percentage of Participants With a Tumor Response
Délai: Baseline to Study completion (Up To 3.5 Years)
|
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1.
Complete Response (CR) is disappearance of all target lesions; Partial Response (PR) is greater than or equal to (≥) 30% decrease in sum of longest diameter of target lesions.
|
Baseline to Study completion (Up To 3.5 Years)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 15678
- I5B-JE-JGDK (Autre identifiant: Eli Lilly and Company)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Olaratumab
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyComplétéGlioblastome Multiforme AdulteÉtats-Unis
-
Eli Lilly and CompanyRésiliéTumeur stromale gastro-intestinale (GIST)États-Unis, Belgique, Allemagne, Pays-Bas, Pologne, Espagne
-
Grupo Espanol de Investigacion en SarcomasActif, ne recrute pas
-
Eli Lilly and CompanyComplété
-
Eli Lilly and CompanyDisponibleSarcome des tissus mousCanada, Italie, Corée, République de, Espagne, Taïwan, États-Unis, L'Autriche, Brésil, Hongrie, Inde, Royaume-Uni
-
Eli Lilly and CompanyComplété
-
Eli Lilly and CompanyMerck Sharp & Dohme LLCComplétéSarcome des tissus mousÉtats-Unis, Belgique, Danemark, France
-
OctapharmaComplétéTrouble d'immunodéficience primaireÉtats-Unis
-
Eli Lilly and CompanyComplétéSarcome des tissus mousÉtats-Unis
-
Eli Lilly and CompanyComplétéSarcome des tissus mousÉtats-Unis, Espagne, France, Italie, Royaume-Uni